Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals. The new findings presented over the weekend show the drug can maintain quality of life in the ...

Novartis announced new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance ...

ZURICH, Dec 12 (Reuters) - Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. DENVER (KDVR) — A Colorado board continues ...

Dec 12 (Reuters) - Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...